The world of medicine and drug development has transformed dramatically over the past 50 years. Today, we have biologic medicines, genomic sequencing technologies, and digital health tools that help patients become more engaged in their care. But one part of the equation hasn’t seen very much change at all: clinical trials. Clinical trials are a … Continue reading “Fixing the Clinical Trial Bottleneck by Making Patients a Priority”
Author: Andreas Koester
Andreas Koester is vice president and global head of Janssen Clinical Innovation, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Koester is leading the company’s efforts to enhance and optimize pharmaceutical clinical trials. His highly specialized, global team is working to solve the pain points of clinical trials through new patient-centric engagement strategies and innovative solutions. As a trusted partner to the five core therapeutic areas at Janssen R&D, Janssen Clinical Innovation identifies and tests promising approaches for clinical trial success and then expertly navigates teams through the entire process of implementation. Driven by a mission to transform the drug-development paradigm by elevating the patient experience throughout, Janssen Clinical Innovation also serves as a central knowledge point within Janssen R&D, creating blueprints for the next generation of clinical trials---as it advances an industry-leading pipeline of new medicines.
Dr. Koester’s background is in drug development, spanning first-in-human, proof-of-concept and large-registration trials. He worked in leadership roles for trials that led to approvals of darunavir (Prezista), etravirine (Intelence), and galantamine (Reminyl). He is a graduate of Leipzig Medical School and earned his Ph.D. in Clinical Pharmacology from Humboldt University in Berlin.